Novel Health Strategies Study Shows Oncology, Diabetes and Auto-Immune Indications Driving Growth of the Biotech Sector; More Products Facing Market Access Challenges
Online PR News – 22-January-2013 – Bethesda, Maryland – Novel Health Strategies LLC, a leading life sciences consulting firm announces the publication of 2011-2012 market trends study called 'What's fueling the biotech engine-2011 to 2012', in Nature Biotechnology. The published article is an analysis of sales, pricing, HEOR, reimbursement trends and competitive dynamics of more than hundred specialty biologic products. This study highlights several emerging trends in the biotech sector.
The key topics and questions covered this article are:
What are the top highest selling classes of products in the biotech sector?
What factors are driving the growth of the biotech sector
What are the sales dynamics for top biotech products?
How has reimbursement and market access impacted growth of the biopharma sector?
Which products showed new trends in pricing strategy?
What is the outlook for products indicated for oncology, diabetes and auto-immune
Which are the most promising biologics and small-molecules products?
What lessons can be learned for biosimilars from recent trends in ESA, G-CSF and HGH products?
What is the overall outlook for biotech sector for 2013-2018?
What are the innovative strategies that are emerging in the biotech sector?
For biopharmaceuticals and device firms, universities, trade organizations and non-profit organizations a complimentary in-person presentation on these trends can be requested by email or phone.
More information about the article series is available at http://novelhealthstrategies.com/thoughtleadership.htm
About What's Fueling the Biotech Engine Series
This article is an annual and recurring series published in Nature Biotechnology since 2006. The article provides strategy overview on clinical, HEOR, sales, pricing, reimbursement, regulatory trends and competitive dynamics for more than hundred specialty biologics. This study is the result of more than five years of cumulative research, analyses and interviews with various stakeholders. This series has been cited and quoted by more than hundred peer-reviewed publications and agencies (FDA, EMA and others). More details about this research are available upon request.
About Novel Health Strategies LLC
Novel Health Strategies, LLC ("Novel Health") is an award winning team of experienced professionals with expertise in healthcare strategy, research, policy, publications, health economics and outcomes research, modeling, and pricing and market access. Novel Health team has led strategy projects for majority of top 50 pharmaceutical, biotech and device companies. Novel Health has large network of internal and external stakeholders and has published several thought leading strategy perspectives. Novel Health has presented industry trends and perspectives at ISPOR, AMCP and BIO meetings.
About The Author
Saurabh (Rob) Aggarwal, PhD is a Principal at Novel Health Strategies, a life sciences consulting firm based in Bethesda, MD. Mr. Aggarwal has led more than hundred US and global market access, HEOR and reimbursement projects for drugs and devices. Before Novel Health, he was at Sanford C. Bernstein, IMS and Parexel. Mr. Aggarwal has published several thought leading articles on healthcare trends and is a frequent speaker at major conferences and meetings. Mr. Aggarwal is the author of this annual recurring series published in Nature Biotechnology, called ‘What’s fueling the biotech engine’, cited by more than two hundred publications. He holds a PhD from The Johns Hopkins University, where he won multiple awards and patents for his work